Prosecution Insights
Last updated: April 19, 2026
Application No. 18/030,374

Lichen Extract-based Formulation for Cervids

Final Rejection §101
Filed
Apr 05, 2023
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zoo Pharma Dynamics LLC
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
80%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
572 granted / 1058 resolved
-5.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
67 currently pending
Career history
1125
Total Applications
across all art units

Statute-Specific Performance

§101
9.5%
-30.5% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1058 resolved cases

Office Action

§101
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. The amendment filed March 2, 2026 has been received and entered. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior Office action. Any rejection set forth in a previous Office action that is not specifically set forth below is withdrawn. 3. Claims 1-24 are pending. Election/Restrictions 4. In the reply filed on August 11, 2025, applicant elected Group I, claims 1-17 without traverse. 5. Claims 18-24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. 6. Claims 1-17 are examined on the merits. Claim Rejections - 35 USC § 101 7. Claims 1-5 and 14-17 are rejected under 35 U.S.C. 101 because the claimed invention is directed to natural products without significantly more for the reasons set forth in the previous Office action. All of applicant’s arguments regarding this ground of rejection have been fully considered but are not persuasive. Applicant argues that the claimed invention is directed to patent eligible subject matter because: Paragraph [0023] indicates that mixing the specified extracts together as commensurate in scope with the stated claims changes the function, or other properties of the extracts in a marked way in comparison with the closest naturally occurring counterpart. More specifically, "Formulations containing the Witch's Hair Lichen (Alectoria Sarmentosa) extract are 75% more digestible than formulations without this extract". Thus, adding Witch's Hair Lichen to the chosen combination of reindeer lichen and lung lichen produces a marked distinction. However, applicant has not provided evidence to support the assertion that the combination of the extracts increases the digestibility of the products. Thus, without evidence to show that the combination produces a marked distinction, the claims are still considered to be properly rejected as being drawn to patent ineligible subject matter. Claim Objections 8. Claims 6-13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Apr 05, 2023
Application Filed
Aug 26, 2025
Non-Final Rejection — §101
Mar 02, 2026
Response Filed
Mar 25, 2026
Final Rejection — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594313
COMPOSITION FOR RELIEVING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS COMPRISING A MIXED EXTRACT OF HOP AND CYNANCHUM WILFORDII AND METHOD FOR TREATING OR ALLEVIATING CARDIOVASCULAR DISEASES OR OSTEOPOROSIS USING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12582674
Methods and Treatment of Trauma
2y 5m to grant Granted Mar 24, 2026
Patent 12569527
TETRASELMIS CHUII (T. CHUII) FOR THE TREATMENT OF MALE INFERTILITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564606
PHARMACEUTICAL COMPOSITION FOR TREATING WOUNDS
2y 5m to grant Granted Mar 03, 2026
Patent 12564551
Composition or oat extract comprising avenanthramide and ß-glucan
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
80%
With Interview (+25.7%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1058 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month